NASDAQ$NUVL
Nuvalent Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Pipeline was advanced, key milestones were reiterated, and financial results were reported.
Nuvalent reported third quarter 2024 financial results, highlighting pipeline progress and reiterating key anticipated milestones. The company's cash position is strong at $1.2 billion, expected to extend operating runway into 2028.
- All anticipated 2024 milestones were achieved, reinforcing progress on OnTarget 2026 operating plan.
- Development timelines were accelerated, supporting the goal of achieving the first approved product in 2026.
- Alice Shaw, M.D., Ph.D., a leading medical oncologist, was appointed to the Scientific Advisory Board.
- A strong cash position of $1.2 billion, including proceeds from an upsized $575 million public offering, is expected to extend the operating runway into 2028.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$0
Forward guidance
Nuvalent is focused on executing its OnTarget 2026 plan, achieving key milestones, and efficiently advancing its programs for patients.
Tailwinds
- Execute on Global Registrational Strategies in 2024
- Report First Pivotal Data in 2025
- Achieve First Approved Product in 2026
- Advance zidesamtinib for ROS1-positive NSCLC
- Advance NVL-655 for ALK-positive NSCLC
Headwinds
- Risks related to clinical trial enrollment and timing
- Potential for unexpected concerns during clinical trials
- Uncertainty of earlier clinical trial results predicting later-stage trials
- Risk of insufficient data to support registration
- Potential for unexpected costs, delays, or other hurdles
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2024
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro